Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
10.54
-0.32 (-2.95%)
Nov 20, 2024, 4:00 PM EST - Market closed
Y-mAbs Therapeutics Employees
Y-mAbs Therapeutics had 100 employees as of December 31, 2023. The number of employees decreased by 47 or -31.97% compared to the previous year.
Employees
100
Change (1Y)
-47
Growth (1Y)
-31.97%
Revenue / Employee
$845,530
Profits / Employee
-$238,640
Market Cap
472.08M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
GRAIL | 1,360 |
Treace Medical Concepts | 516 |
REGENXBIO | 344 |
Esperion Therapeutics | 240 |
Arcturus Therapeutics Holdings | 180 |
Acelyrin | 135 |
Theravance Biopharma | 99 |
PureTech Health | 90 |
YMAB News
- 12 days ago - Y-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments - GlobeNewsWire
- 17 days ago - Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan - GlobeNewsWire
- 27 days ago - Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast - GlobeNewsWire
- 7 weeks ago - Y-mAbs to Participate in Upcoming Investor Conferences in October - GlobeNewsWire
- 2 months ago - Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research - GlobeNewsWire
- 2 months ago - Y-mAbs to Participate in Upcoming Investor Conferences in September - GlobeNewsWire
- 3 months ago - Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade) - Seeking Alpha